We found that the expression of TUBA1B, one of the current therapeutic targets for cancer drugs, increased simultaneously with the expression of DNB gene CCT6A. TUBA1B, a DNB-neighboring DEG in pre-exhausted CD8+ T cells, was significantly associated with the overall survival of CRC patients (p = 0.0082) (Figure 3E). The gene discussed is CCT6A; the disease is cancer.